Pacific Hospital Supply (4126) reported revenue of NT$203.6 million for Oct 2026, -6.3% year on year and -7.3% from the previous month. Revenue for Jan–Oct 2026 was NT$2.06 billion (+0.4% year on year).
In Oct 2026, it ranked No. 39 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$203.6 million | -6.3% | -7.3% |
| Sep 2026 | NT$219.6 million | +3.0% | -1.5% |
| Aug 2026 | NT$223.1 million | +0.4% | -0.7% |
| Jul 2026 | NT$224.7 million | +0.5% | +8.3% |
| Jun 2026 | NT$207.4 million | +18.2% | -2.3% |
| May 2026 | NT$212.2 million | -2.0% | +15.7% |
| Apr 2026 | NT$183.4 million | +5.6% | -22.3% |
| Mar 2026 | NT$236 million | -7.3% | +62.2% |
| Feb 2026 | NT$145.5 million | -18.0% | -27.3% |
| Jan 2026 | NT$200.2 million | +16.0% | +3.4% |
| Dec 2025 | NT$193.5 million | -11.4% | +16.9% |
| Nov 2025 | NT$165.6 million | -25.7% | -23.8% |
| Oct 2025 | NT$217.4 million | +9.8% | +1.9% |
| Sep 2025 | NT$213.3 million | +25.7% | -4.0% |
| Aug 2025 | NT$222.3 million | +3.4% | -0.6% |
| Jul 2025 | NT$223.6 million | +15.0% | +27.4% |
| Jun 2025 | NT$175.5 million | -10.6% | -18.9% |
| May 2025 | NT$216.5 million | +13.3% | +24.6% |
| Apr 2025 | NT$173.8 million | -1.0% | -31.7% |
| Mar 2025 | NT$254.5 million | +12.4% | +43.4% |
| Feb 2025 | NT$177.4 million | +24.6% | +2.8% |
| Jan 2025 | NT$172.6 million | -11.6% | -21.0% |
| Dec 2024 | NT$218.4 million | +29.0% | -2.0% |
| Nov 2024 | NT$222.9 million | +28.7% | +12.5% |
| Oct 2024 | NT$198.1 million | +11.7% | +16.7% |
Jan–Oct 2026 cumulative: NT$2.06 billion (+0.4% YoY)
Other Biotech & Medical companies
Compare with peers: Pacific Hospital Supply vs PEC / Pacific Hospital Supply vs Lotus Pharm / Pacific Hospital Supply vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16